Local view for "http://purl.org/linkedpolitics/eu/plenary/2009-01-13-Speech-2-382"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2009-01-13"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmaceutical products package (debate)2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20090113.29.2-382"2
lpv:hasSubsequent	lp_eu:2009-01-13-Speech-2-3832
lpv:speaker	lp:Anne Ferreira2
lpv:spokenAs	member; ENVI (2007-01-31--2009-07-13)3 substitute; Temporary Committee on Climate Change (2007-05-10--2009-02-04)3 member; Delegation for relations with South Africa (2007-03-14--2009-07-13)3 substitute; LIBE (2007-01-31--2009-07-13)3 substitute; Delegation to the EU-Kazakhstan, EU-Kyrgyzstan and EU-Uzbekistan Parliamentary Cooperation Committees, and for relations with Tajikistan, Turkmenistan and Mongolia (2004-09-15--2009-07-13)3 member; PES (2004-07-20--2009-07-13)3 unknown; Parti socialiste (2004-07-20--2009-07-13)3
lpv:translated text	"Madam President, Commissioner, ladies and gentlemen, it always surprises me when health matters are handled by the Directorate-General for Enterprise and Industry. On reading the proposals on patient information, however, it soon becomes apparent that, one or two nuances aside, they treat medicines as if they were any other consumer product. On this issue, I believe that information provided by the industry itself, other than labelling and statutory notices, is called advertising and it is by repetition that it becomes a competitive commercial asset. The Commission may well put forward certain provisions to define its proposals, and it may keep telling us that it is patient associations that are impatiently awaiting such provisions. There are many of us who are not fooled by the impact of this ‘patient information’ directive and know that it will have no benefit in actually improving the health of Europeans. We can already be certain that, if the text were to be adopted, the pharmaceutical industry’s marketing budget would skyrocket, undoubtedly at the expense of research. Already today, 23% of turnover is dedicated to advertising and only 17% to research, and if we look at the United States and New Zealand, where this advertising information is already permitted, we can see that it has led to an increase in the number of prescriptions and health costs, without any visible improvement in the quality of care or in citizens’ health. Let this be a lesson to us. Finally, I would like to conclude by saying that a modern solution would be to have more faith in health professionals, or to train them better, so that they can provide information on treatments and prescription medicines."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph